B- type natriuretic peptide during treatment with sacu- bitril/valsartan: the PARADIGM-HF trial. J Am Coll Cardiol. 2019;73:1264 72. 9. Senni M, McMurray JJV, Wachter R, et al. Impact of systolic blood pressure on the safety and tolerability of initiating and up-titrating sacubitril/valsartan in pa- tients with heart failure and reduced ejection fraction: insights from the TITRATION study. Eur J Heart Fail. 2018;20:491 500. 10. Khariton Y, Fonarow GC, Arnold SV, et al. Associ- ation between sacubitril/valsartan initiation and health status outcomes in heart failure with reduced ejection fraction. J Am Coll Cardiol HF. 2019;7:933 41. 11. Januzzi JL Jr., Prescott MF, Butler J, et al. Associ- ation of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in pa- tients with heart failure with reduced ejection fraction. JAMA. 2019;322:1 11. 12. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagli ozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995 2008. 13. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagli ozin in heart failure. N Engl J Med. 2020;383:1413 24. 14. Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure. J Am Coll Cardiol HF. 2014;2:663 70. 15. Packer M, Califf RM, Konstam MA, et al. Compari- son of omapatrilat and enalapril in patients with chronic heart failure: the omapatrilat versus enalapril randomized trial of utility in reducing events (OVER- TURE). Circulation. 2002;106:920 6. 16. McMurray JJ, Packer M, Desai AS, et al. Angio- tensin neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993 1004. 17. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. 